Table 20: Clinical evidence profile: levodopa versus placebo

Quality assessment							№ of patients		Effect			
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Levodopa	placebo	Relative (95% CI)	Absolute (95% CI)	Quality	Importance
HRQoL - not reported												
-	-	-	-	-	-	-	-	-	-	-	-	CRITICAL
Dystonia - not reported												
-	-	-	-	-	-	-	-	-	-	-	-	CRITICAL
Satisfaction - not reported												
-	-	-	-	-	-	-	-	-	-	-	-	CRITICAL
Change in motor function from pre-treatment (follow up: 2 weeks; assessed with: QUEST score; Scale from: 0 to 100)												
1	randomised trials	serious [1]	not serious	not serious	serious [2]	none	9	9	-	MD 5.92 % higher (1.72 lower to 13.56 higher)	LOW	CRITICAL
Adverse events												
1	randomised trials	very serious [1,3]	not serious	not serious	serious [2]	none	No adverse events reported [4]				VERY LOW	IMPORTANT
Goal attainment scores - not reported												
-	-	-	-	-	-	-	-	-	-	-	-	IMPORTANT

Quality assessment							№ of patients		Effect			
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Levodopa	placebo	Relative (95% CI)	Absolute (95% CI)	Quality	Importance
Pain - not reported												
-	-	-	-	-	-	-	-	-	-	-	-	IMPORTANT

CI: confidence interval; HRQoL: health related quality of life; MD: mean difference
1 Unclear randomisation method
2. Confidence interval for effect includes one default MID threshold
3. Adverse events were not systematically monitored.
4. No events reported